MedTrace Logo

Fruquintinib Combined With TAS102 for Advanced Gastric Cancer

NCT06102785 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2023-10-26

No results posted yet for this study

Summary

This is a prospective, single-center, open, single-arm clinical study to observe and evaluate the efficacy and safety of Fruquintinib combined with TAS102 for second-line treatment of advanced gastric cancer.

Conditions

Interventions

DRUG

Fruquintinib, TAS102

Fruquintinib combined with TAS102

Sponsors & Collaborators

  • Tianjin Medical University Cancer Institute and Hospital

    lead OTHER

Principal Investigators

  • Ting Deng, MD · Tianjin Medical University Cancer Institute and Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-10
Primary Completion
2026-10-10
Completion
2026-10-10

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06102785 on ClinicalTrials.gov